3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Glioma
3
Thyroid Carcinoma, Anaplastic
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sexual Dysfunction, Physiological
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Melanoma, Cutaneous Malignant
1
Lymphoproliferative Disorders
1
Lymphoma
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Gastrointestinal Neoplasms
1
Interventions
Pemetrexed
7
Carboplatin
7
Cisplatin
5
pembrolizumab
4
durvalumab
4
osimertinib
3
Paclitaxel
3
selpercatinib
2
pralsetinib
2
cobimetinib
2
Radiosurgery
2
Erlotinib Hydrochloride
2
130-nm albumin-bound paclitaxel
2
trametinib
1
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
napabucasin
1
glutathione pegylated liposomal doxorubicin
1
ficlatuzumab
1
exemestane
1
enzalutamide
1
entinostat
1
dabrafenib
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
dabrafenib
×
Thoracic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled